MA53973A - Inhibiteurs de la réplication du virus de l'immunodéficience humaine - Google Patents

Inhibiteurs de la réplication du virus de l'immunodéficience humaine

Info

Publication number
MA53973A
MA53973A MA053973A MA53973A MA53973A MA 53973 A MA53973 A MA 53973A MA 053973 A MA053973 A MA 053973A MA 53973 A MA53973 A MA 53973A MA 53973 A MA53973 A MA 53973A
Authority
MA
Morocco
Prior art keywords
immunodeficiency virus
human immunodeficiency
virus replication
replication inhibitors
inhibitors
Prior art date
Application number
MA053973A
Other languages
English (en)
Inventor
Eric P Gillis
Kyle E Parcella
Manoj Patel
Kevin M Peese
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68344933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53973(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MA53973A publication Critical patent/MA53973A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA053973A 2018-10-24 2019-10-22 Inhibiteurs de la réplication du virus de l'immunodéficience humaine MA53973A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862749818P 2018-10-24 2018-10-24

Publications (1)

Publication Number Publication Date
MA53973A true MA53973A (fr) 2022-02-09

Family

ID=68344933

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053973A MA53973A (fr) 2018-10-24 2019-10-22 Inhibiteurs de la réplication du virus de l'immunodéficience humaine

Country Status (25)

Country Link
US (2) US11541055B2 (fr)
EP (1) EP3870577B1 (fr)
JP (1) JP7398448B2 (fr)
KR (1) KR20210084508A (fr)
CN (1) CN113195475A (fr)
AR (1) AR116798A1 (fr)
AU (1) AU2019364739B2 (fr)
BR (1) BR112021007362A2 (fr)
CA (1) CA3117289A1 (fr)
CL (1) CL2021001025A1 (fr)
CO (1) CO2021004679A2 (fr)
CR (1) CR20210207A (fr)
DO (1) DOP2021000062A (fr)
EA (1) EA202190854A1 (fr)
ES (1) ES3026145T3 (fr)
IL (1) IL282240B2 (fr)
MA (1) MA53973A (fr)
MX (1) MX2021004593A (fr)
PE (1) PE20211781A1 (fr)
PH (1) PH12021550813A1 (fr)
PL (1) PL3870577T3 (fr)
PT (1) PT3870577T (fr)
SG (1) SG11202103560YA (fr)
TW (1) TWI824041B (fr)
WO (1) WO2020084492A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3774775B8 (fr) * 2018-04-11 2023-11-15 VIIV Healthcare UK (No.5) Limited Composés de 4-oxo-3,4-dihydroquinazoline utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3643711A1 (fr) 2018-10-24 2020-04-29 Bayer Animal Health GmbH Nouveaux composés anthelminthiques
US11541055B2 (en) * 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
BR112021025655A2 (pt) * 2019-06-19 2022-02-01 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
US20220370451A1 (en) * 2019-10-08 2022-11-24 VIIV HEALTHCARE UK ( No. 5) LIMITED Inhibitors of human immunodeficiency virus replication
EP4066839A4 (fr) 2019-11-28 2023-12-27 Shionogi & Co., Ltd Agent pharmaceutique prophylactique et thérapeutique pour maladies infectieuses à vih, caractérisé en ce qu'il comprend une combinaison d'un inhibiteur d'intégrase et d'un agent anti-vih
JP7703538B2 (ja) * 2019-12-09 2025-07-07 ヴィーブ、ヘルスケア、カンパニー カボテグラビルを含んでなる医薬組成物
BR112022020933A2 (pt) * 2020-04-15 2022-12-06 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
MX2024004551A (es) * 2021-10-13 2024-06-26 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de inmunodeficiencia humana.
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
CN121335877A (zh) 2023-06-15 2026-01-13 Viiv保健英国第五有限公司 用于制备化合物的方法和中间体
AU2024353051A1 (en) 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
AU2023466962A1 (en) 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
TW202547514A (zh) 2024-02-05 2025-12-16 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004023100D1 (de) 2003-10-08 2009-10-22 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidemie
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
JP2012201642A (ja) * 2011-03-25 2012-10-22 Tsutomu Takeuchi 1−フェニルピロリジン−2,5−ジオン誘導体を有効成分とするbaffの結合阻害剤
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
ES2642265T3 (es) 2013-01-09 2017-11-16 Gilead Sciences, Inc. Compuestos terapéuticos para el tratamiento de infecciones virales
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130966A1 (fr) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Agents antiviraux
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
US10065953B2 (en) * 2014-08-27 2018-09-04 VIIV Healthcare UK (No.5) Limited Imidazo[1,2-A]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication
EP3186239B1 (fr) * 2014-08-29 2018-10-10 Gilead Sciences, Inc. Agents antiretroviraux
CN119462611A (zh) 2016-08-19 2025-02-18 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ, インコーポレイテッド ピリジン誘導体およびhiv感染を処置するためのその使用
EP3752496B1 (fr) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Procédés et intermédiaires pour préparer un composé thérapeutique utile dans le traitement d'une infection virale par retroviridae
EP3774775B8 (fr) * 2018-04-11 2023-11-15 VIIV Healthcare UK (No.5) Limited Composés de 4-oxo-3,4-dihydroquinazoline utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3833436A1 (fr) 2018-08-09 2021-06-16 VIIV Healthcare UK (No.5) Limited Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3849982A1 (fr) 2018-09-14 2021-07-21 VIIV Healthcare UK (No.5) Limited Inhibiteurs de la réplication du virus de l'immunodéficience humaine
JP7433303B2 (ja) 2018-09-20 2024-02-19 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
FR3086760A1 (fr) 2018-10-02 2020-04-03 Institut Mines Telecom Procede d'evaluation de la resistance mecanique d'un echantillon de tissu biologique
US11541055B2 (en) * 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
ES2971987T3 (es) 2018-10-24 2024-06-10 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de inmunodeficiencia humana
JP7500555B2 (ja) 2018-10-25 2024-06-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
EP3873607B1 (fr) 2018-10-29 2023-11-29 VIIV Healthcare UK (No.5) Limited Dérivés de quinazolinyle-indazole et leur utilisation en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
US20210395248A1 (en) 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP2022506399A (ja) 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
US11429555B2 (en) 2019-02-26 2022-08-30 Apple Inc. Coprocessors with bypass optimization, variable grid architecture, and fused vector operations
CA3078001A1 (fr) 2019-04-11 2020-10-15 Goli Nutrition Inc. Additif nutritionnel au vinaigre de cidre de pomme
US20220211704A1 (en) 2019-04-30 2022-07-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
BR112021025655A2 (pt) 2019-06-19 2022-02-01 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
EP4038068A1 (fr) 2019-10-01 2022-08-10 VIIV Healthcare UK (No.5) Limited Dérivés de-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yle n-substitués utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP4038064B1 (fr) 2019-10-01 2024-02-21 VIIV Healthcare UK (No.5) Limited Dérivés de 6-oxo-1,6-dihydropyrimidine-2-yl n-substitués utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
TW202128648A (zh) 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
EP4114527A1 (fr) 2020-03-06 2023-01-11 VIIV Healthcare UK (No.5) Limited Inhibiteurs de la réplication du virus de l'immunodéficience humaine

Also Published As

Publication number Publication date
TW202031261A (zh) 2020-09-01
WO2020084492A1 (fr) 2020-04-30
PH12021550813A1 (en) 2021-10-04
IL282240B2 (en) 2025-05-01
CA3117289A1 (fr) 2020-04-30
EP3870577A1 (fr) 2021-09-01
PL3870577T3 (pl) 2025-06-16
CO2021004679A2 (es) 2021-04-30
CR20210207A (es) 2021-09-02
EP3870577B1 (fr) 2025-03-19
PT3870577T (pt) 2025-04-07
MX2021004593A (es) 2021-06-15
US11541055B2 (en) 2023-01-03
AU2019364739A1 (en) 2021-05-20
JP2022505841A (ja) 2022-01-14
JP7398448B2 (ja) 2023-12-14
KR20210084508A (ko) 2021-07-07
CL2021001025A1 (es) 2021-11-05
IL282240A (en) 2021-05-31
DOP2021000062A (es) 2021-09-15
IL282240B1 (en) 2025-01-01
AU2019364739B2 (en) 2022-05-26
TWI824041B (zh) 2023-12-01
SG11202103560YA (en) 2021-05-28
US20200360384A1 (en) 2020-11-19
AR116798A1 (es) 2021-06-16
CN113195475A (zh) 2021-07-30
US20230109662A1 (en) 2023-04-06
PE20211781A1 (es) 2021-09-08
BR112021007362A2 (pt) 2021-07-20
ES3026145T3 (en) 2025-06-10
EA202190854A1 (ru) 2021-08-17

Similar Documents

Publication Publication Date Title
MA53973A (fr) Inhibiteurs de la réplication du virus de l'immunodéficience humaine
NO2025052I1 (no) a combination of (a) vanzacaftor or a pharmaceutically acceptable salt thereof, preferably a calcium salt thereof, (b) tezacaftor or a pharmaceutically acceptable salt thereof, and (c) deutivacaftor or a pharmaceutically acceptable salt thereof
PT3619205T (pt) Inibidores da replicação do vírus da imunodeficiência humana
PT3870575T (pt) Inibidores da replicação do vírus da imunodeficiência humana
EP2220095A4 (fr) Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP2220076A4 (fr) Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP2220084A4 (fr) Inhibiteurs de la réplication du virus de l'immunodéficience humaine
CU24498B1 (es) Anticuerpos de factor xi
PT3917930T (pt) Inibidores da replicação do vírus da imunodeficiência humana
IL280475A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EP3827837A4 (fr) Composition visant à prévenir et traiter des maladies liées au système immunitaire
EP3780979C0 (fr) Sous-vêtement pour homme
EP3747459A4 (fr) Nouvel immunoadjuvant vaccinal
MA42614A (fr) Dérivés d'acide 5-(n-benzyl tétrahydroisoquinolin-6-yl) pyridin-3-yl-acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3811918A4 (fr) Fauteuil roulant
EP4038064C0 (fr) Dérivés de 6-oxo-1,6-dihydropyrimidine-2-yl n-substitués utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3592377A4 (fr) Formes posologiques de kallicréine tissulaire 1
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
EP4062884A4 (fr) Couche jetable
IL311982A (en) Inhibitors of human immunodeficiency virus replication
DK3863580T3 (da) Engangsble
EP3773400C0 (fr) Fauteuil roulant
EP3634583A4 (fr) Implant à action prolongée pour le traitement de maladies infectieuses
IL258238B (en) Hiv antibody compositions and methods of use
PL4072532T3 (pl) Postać dawkowania do zastosowania w leczeniu lub zapobieganiu chorobie